Hearing preservation after low dose linac radiosurgery for acoustic neuroma depends on initial hearing and time

Abstract Purpose To assess long term outcomes and factors determining hearing preservation after low dose linac stereotactic radiosurgery (SRS) for acoustic neuroma (AN) at the Royal Adelaide Hospital using prospectively collected data. Material and methods Between 1994 and 2010, 102 patients had SR...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Radiotherapy and oncology 2011-12, Vol.101 (3), p.420-424
Hauptverfasser: Roos, Daniel E, Potter, Andrew E, Zacest, Andrew C
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 424
container_issue 3
container_start_page 420
container_title Radiotherapy and oncology
container_volume 101
creator Roos, Daniel E
Potter, Andrew E
Zacest, Andrew C
description Abstract Purpose To assess long term outcomes and factors determining hearing preservation after low dose linac stereotactic radiosurgery (SRS) for acoustic neuroma (AN) at the Royal Adelaide Hospital using prospectively collected data. Material and methods Between 1994 and 2010, 102 patients had SRS for AN. Five patients had neurofibromatosis type 2, six sporadic cases had relapsed after surgery, and the remaining 91 sporadic cases had primary SRS. Dose was 12 or 14 Gy. Sustained changes ⩾ 2 mm in any diameter were deemed significant, and useful hearing was defined as inter-aural pure tone average (PTA) ⩽ 50 dB. Possible prognostic factors for hearing retention were tested by dividing the patients at pre-specified cutpoints: age (60 years), maximum tumour diameter (20 mm), initial PTA (20 dB) and dose (12 vs 14 Gy). Results Eighty-four of the 91 sporadic primary SRS cases were evaluable for tumour control with at least one post-treatment MRI. Their median follow-up was 65 mo (range 10–184 mo). Eighty-two (97.6%) were controlled, the remaining two requiring salvage surgery for progression at 5.75 and 9.75 years. Also, one of the post-operative cases required surgery at 2.1 years after SRS. For the 50 sporadic primary SRS patients with initially useful hearing, median age was 56 (range 21–76), median initial PTA 16 dB (range −11 to +45 dB) and median tumour diameter 21 mm (range 10–33 mm). Four received 14 Gy, the rest 12 Gy. After SRS, 19 patients (38%) retained useful hearing. The Kaplan–Meier estimated preservation rate at 5 years was 50% (95% CI 36–64%) but by 10 years, this had fallen to 23% (95% CI 12–41%). On univariate analysis, the only significant factor was initial PTA ( P < 0.0001). The estimated risk of hearing loss after SRS for patients with initial PTA ⩾ 20 dB was 5.0 (95% CI 2.2–11.2) times that with PTA < 20 dB. Conclusions Tumour control was excellent (99/102 = 97% freedom from surgical salvage). Hearing preservation was strongly dependent on initial PTA, but there was a steady fall-off in hearing out to at least 10 years.
doi_str_mv 10.1016/j.radonc.2011.06.035
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_906559578</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S016781401100346X</els_id><sourcerecordid>906559578</sourcerecordid><originalsourceid>FETCH-LOGICAL-c482t-277b0370858075958120eaa200603b2103754e8d10d8bd3af3b136056704ff63</originalsourceid><addsrcrecordid>eNqFkTFvFDEQhS0EIkfgHyDkjmqXsb1r-xokFAUSKRIFKegsrz0bfOzah70bdP8en-6goEnlwm_em_keIW8ZtAyY_LBrs_UpupYDYy3IFkT_jGyYVtsGtFbPyabKVKNZBxfkVSk7AOAg1EtywZnqmGJ6Q9IN2hziA91nLJgf7RJSpHZcMNMp_aY-FaRTiNbRGhdSWfMD5gMdU6bWpbUswdGIa06zpR73GH2h1SHEsAQ70R9nexs9XcKMr8mL0U4F35zfS3L_-fr-6qa5-_rl9urTXeM6zZeGKzXUVUH3GlS_7TXjgNZyAAli4Kz-9R1qz8DrwQs7ioEJCb1U0I2jFJfk_cl2n9OvFcti5lAcTpONWJc2W5B9tVW6KruT0uVUSsbR7HOYbT4YBuYI2uzMCbQ5gjYgTQVdx96dA9ZhRv9v6C_ZKvh4EmC98jFgNsUFjA59yOgW41N4KuF_A1d7CM5OP_GAZZfWHCtBw0zhBsy3Y9nHrhkDEJ38Lv4A2cWl1Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>906559578</pqid></control><display><type>article</type><title>Hearing preservation after low dose linac radiosurgery for acoustic neuroma depends on initial hearing and time</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Roos, Daniel E ; Potter, Andrew E ; Zacest, Andrew C</creator><creatorcontrib>Roos, Daniel E ; Potter, Andrew E ; Zacest, Andrew C</creatorcontrib><description>Abstract Purpose To assess long term outcomes and factors determining hearing preservation after low dose linac stereotactic radiosurgery (SRS) for acoustic neuroma (AN) at the Royal Adelaide Hospital using prospectively collected data. Material and methods Between 1994 and 2010, 102 patients had SRS for AN. Five patients had neurofibromatosis type 2, six sporadic cases had relapsed after surgery, and the remaining 91 sporadic cases had primary SRS. Dose was 12 or 14 Gy. Sustained changes ⩾ 2 mm in any diameter were deemed significant, and useful hearing was defined as inter-aural pure tone average (PTA) ⩽ 50 dB. Possible prognostic factors for hearing retention were tested by dividing the patients at pre-specified cutpoints: age (60 years), maximum tumour diameter (20 mm), initial PTA (20 dB) and dose (12 vs 14 Gy). Results Eighty-four of the 91 sporadic primary SRS cases were evaluable for tumour control with at least one post-treatment MRI. Their median follow-up was 65 mo (range 10–184 mo). Eighty-two (97.6%) were controlled, the remaining two requiring salvage surgery for progression at 5.75 and 9.75 years. Also, one of the post-operative cases required surgery at 2.1 years after SRS. For the 50 sporadic primary SRS patients with initially useful hearing, median age was 56 (range 21–76), median initial PTA 16 dB (range −11 to +45 dB) and median tumour diameter 21 mm (range 10–33 mm). Four received 14 Gy, the rest 12 Gy. After SRS, 19 patients (38%) retained useful hearing. The Kaplan–Meier estimated preservation rate at 5 years was 50% (95% CI 36–64%) but by 10 years, this had fallen to 23% (95% CI 12–41%). On univariate analysis, the only significant factor was initial PTA ( P &lt; 0.0001). The estimated risk of hearing loss after SRS for patients with initial PTA ⩾ 20 dB was 5.0 (95% CI 2.2–11.2) times that with PTA &lt; 20 dB. Conclusions Tumour control was excellent (99/102 = 97% freedom from surgical salvage). Hearing preservation was strongly dependent on initial PTA, but there was a steady fall-off in hearing out to at least 10 years.</description><identifier>ISSN: 0167-8140</identifier><identifier>EISSN: 1879-0887</identifier><identifier>DOI: 10.1016/j.radonc.2011.06.035</identifier><identifier>PMID: 21741718</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Acoustic neuroma ; Adult ; Aged ; Aged, 80 and over ; Female ; Hearing ; Hearing preservation ; Hematology, Oncology and Palliative Medicine ; Humans ; Linac radiosurgery ; Male ; Middle Aged ; Neuroma, Acoustic - physiopathology ; Neuroma, Acoustic - surgery ; Radiosurgery - adverse effects ; Radiosurgery - methods ; Time Factors ; Tumour control</subject><ispartof>Radiotherapy and oncology, 2011-12, Vol.101 (3), p.420-424</ispartof><rights>2011</rights><rights>Crown Copyright © 2011. Published by Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c482t-277b0370858075958120eaa200603b2103754e8d10d8bd3af3b136056704ff63</citedby><cites>FETCH-LOGICAL-c482t-277b0370858075958120eaa200603b2103754e8d10d8bd3af3b136056704ff63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.radonc.2011.06.035$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21741718$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roos, Daniel E</creatorcontrib><creatorcontrib>Potter, Andrew E</creatorcontrib><creatorcontrib>Zacest, Andrew C</creatorcontrib><title>Hearing preservation after low dose linac radiosurgery for acoustic neuroma depends on initial hearing and time</title><title>Radiotherapy and oncology</title><addtitle>Radiother Oncol</addtitle><description>Abstract Purpose To assess long term outcomes and factors determining hearing preservation after low dose linac stereotactic radiosurgery (SRS) for acoustic neuroma (AN) at the Royal Adelaide Hospital using prospectively collected data. Material and methods Between 1994 and 2010, 102 patients had SRS for AN. Five patients had neurofibromatosis type 2, six sporadic cases had relapsed after surgery, and the remaining 91 sporadic cases had primary SRS. Dose was 12 or 14 Gy. Sustained changes ⩾ 2 mm in any diameter were deemed significant, and useful hearing was defined as inter-aural pure tone average (PTA) ⩽ 50 dB. Possible prognostic factors for hearing retention were tested by dividing the patients at pre-specified cutpoints: age (60 years), maximum tumour diameter (20 mm), initial PTA (20 dB) and dose (12 vs 14 Gy). Results Eighty-four of the 91 sporadic primary SRS cases were evaluable for tumour control with at least one post-treatment MRI. Their median follow-up was 65 mo (range 10–184 mo). Eighty-two (97.6%) were controlled, the remaining two requiring salvage surgery for progression at 5.75 and 9.75 years. Also, one of the post-operative cases required surgery at 2.1 years after SRS. For the 50 sporadic primary SRS patients with initially useful hearing, median age was 56 (range 21–76), median initial PTA 16 dB (range −11 to +45 dB) and median tumour diameter 21 mm (range 10–33 mm). Four received 14 Gy, the rest 12 Gy. After SRS, 19 patients (38%) retained useful hearing. The Kaplan–Meier estimated preservation rate at 5 years was 50% (95% CI 36–64%) but by 10 years, this had fallen to 23% (95% CI 12–41%). On univariate analysis, the only significant factor was initial PTA ( P &lt; 0.0001). The estimated risk of hearing loss after SRS for patients with initial PTA ⩾ 20 dB was 5.0 (95% CI 2.2–11.2) times that with PTA &lt; 20 dB. Conclusions Tumour control was excellent (99/102 = 97% freedom from surgical salvage). Hearing preservation was strongly dependent on initial PTA, but there was a steady fall-off in hearing out to at least 10 years.</description><subject>Acoustic neuroma</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Female</subject><subject>Hearing</subject><subject>Hearing preservation</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Linac radiosurgery</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neuroma, Acoustic - physiopathology</subject><subject>Neuroma, Acoustic - surgery</subject><subject>Radiosurgery - adverse effects</subject><subject>Radiosurgery - methods</subject><subject>Time Factors</subject><subject>Tumour control</subject><issn>0167-8140</issn><issn>1879-0887</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkTFvFDEQhS0EIkfgHyDkjmqXsb1r-xokFAUSKRIFKegsrz0bfOzah70bdP8en-6goEnlwm_em_keIW8ZtAyY_LBrs_UpupYDYy3IFkT_jGyYVtsGtFbPyabKVKNZBxfkVSk7AOAg1EtywZnqmGJ6Q9IN2hziA91nLJgf7RJSpHZcMNMp_aY-FaRTiNbRGhdSWfMD5gMdU6bWpbUswdGIa06zpR73GH2h1SHEsAQ70R9nexs9XcKMr8mL0U4F35zfS3L_-fr-6qa5-_rl9urTXeM6zZeGKzXUVUH3GlS_7TXjgNZyAAli4Kz-9R1qz8DrwQs7ioEJCb1U0I2jFJfk_cl2n9OvFcti5lAcTpONWJc2W5B9tVW6KruT0uVUSsbR7HOYbT4YBuYI2uzMCbQ5gjYgTQVdx96dA9ZhRv9v6C_ZKvh4EmC98jFgNsUFjA59yOgW41N4KuF_A1d7CM5OP_GAZZfWHCtBw0zhBsy3Y9nHrhkDEJ38Lv4A2cWl1Q</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>Roos, Daniel E</creator><creator>Potter, Andrew E</creator><creator>Zacest, Andrew C</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20111201</creationdate><title>Hearing preservation after low dose linac radiosurgery for acoustic neuroma depends on initial hearing and time</title><author>Roos, Daniel E ; Potter, Andrew E ; Zacest, Andrew C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c482t-277b0370858075958120eaa200603b2103754e8d10d8bd3af3b136056704ff63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Acoustic neuroma</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Female</topic><topic>Hearing</topic><topic>Hearing preservation</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Linac radiosurgery</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neuroma, Acoustic - physiopathology</topic><topic>Neuroma, Acoustic - surgery</topic><topic>Radiosurgery - adverse effects</topic><topic>Radiosurgery - methods</topic><topic>Time Factors</topic><topic>Tumour control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roos, Daniel E</creatorcontrib><creatorcontrib>Potter, Andrew E</creatorcontrib><creatorcontrib>Zacest, Andrew C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Radiotherapy and oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roos, Daniel E</au><au>Potter, Andrew E</au><au>Zacest, Andrew C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hearing preservation after low dose linac radiosurgery for acoustic neuroma depends on initial hearing and time</atitle><jtitle>Radiotherapy and oncology</jtitle><addtitle>Radiother Oncol</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>101</volume><issue>3</issue><spage>420</spage><epage>424</epage><pages>420-424</pages><issn>0167-8140</issn><eissn>1879-0887</eissn><abstract>Abstract Purpose To assess long term outcomes and factors determining hearing preservation after low dose linac stereotactic radiosurgery (SRS) for acoustic neuroma (AN) at the Royal Adelaide Hospital using prospectively collected data. Material and methods Between 1994 and 2010, 102 patients had SRS for AN. Five patients had neurofibromatosis type 2, six sporadic cases had relapsed after surgery, and the remaining 91 sporadic cases had primary SRS. Dose was 12 or 14 Gy. Sustained changes ⩾ 2 mm in any diameter were deemed significant, and useful hearing was defined as inter-aural pure tone average (PTA) ⩽ 50 dB. Possible prognostic factors for hearing retention were tested by dividing the patients at pre-specified cutpoints: age (60 years), maximum tumour diameter (20 mm), initial PTA (20 dB) and dose (12 vs 14 Gy). Results Eighty-four of the 91 sporadic primary SRS cases were evaluable for tumour control with at least one post-treatment MRI. Their median follow-up was 65 mo (range 10–184 mo). Eighty-two (97.6%) were controlled, the remaining two requiring salvage surgery for progression at 5.75 and 9.75 years. Also, one of the post-operative cases required surgery at 2.1 years after SRS. For the 50 sporadic primary SRS patients with initially useful hearing, median age was 56 (range 21–76), median initial PTA 16 dB (range −11 to +45 dB) and median tumour diameter 21 mm (range 10–33 mm). Four received 14 Gy, the rest 12 Gy. After SRS, 19 patients (38%) retained useful hearing. The Kaplan–Meier estimated preservation rate at 5 years was 50% (95% CI 36–64%) but by 10 years, this had fallen to 23% (95% CI 12–41%). On univariate analysis, the only significant factor was initial PTA ( P &lt; 0.0001). The estimated risk of hearing loss after SRS for patients with initial PTA ⩾ 20 dB was 5.0 (95% CI 2.2–11.2) times that with PTA &lt; 20 dB. Conclusions Tumour control was excellent (99/102 = 97% freedom from surgical salvage). Hearing preservation was strongly dependent on initial PTA, but there was a steady fall-off in hearing out to at least 10 years.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>21741718</pmid><doi>10.1016/j.radonc.2011.06.035</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0167-8140
ispartof Radiotherapy and oncology, 2011-12, Vol.101 (3), p.420-424
issn 0167-8140
1879-0887
language eng
recordid cdi_proquest_miscellaneous_906559578
source MEDLINE; Elsevier ScienceDirect Journals
subjects Acoustic neuroma
Adult
Aged
Aged, 80 and over
Female
Hearing
Hearing preservation
Hematology, Oncology and Palliative Medicine
Humans
Linac radiosurgery
Male
Middle Aged
Neuroma, Acoustic - physiopathology
Neuroma, Acoustic - surgery
Radiosurgery - adverse effects
Radiosurgery - methods
Time Factors
Tumour control
title Hearing preservation after low dose linac radiosurgery for acoustic neuroma depends on initial hearing and time
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T22%3A33%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hearing%20preservation%20after%20low%20dose%20linac%20radiosurgery%20for%20acoustic%20neuroma%20depends%20on%20initial%20hearing%20and%20time&rft.jtitle=Radiotherapy%20and%20oncology&rft.au=Roos,%20Daniel%20E&rft.date=2011-12-01&rft.volume=101&rft.issue=3&rft.spage=420&rft.epage=424&rft.pages=420-424&rft.issn=0167-8140&rft.eissn=1879-0887&rft_id=info:doi/10.1016/j.radonc.2011.06.035&rft_dat=%3Cproquest_cross%3E906559578%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=906559578&rft_id=info:pmid/21741718&rft_els_id=S016781401100346X&rfr_iscdi=true